

AUSTRALIAN UNIT TRUST

T. Rowe Price Global Impact Equity Fund– Proxy Voting Summary

6 months ending 30 June 2024

PROXY VOTING PROGRAM OVERVIEW

Proxy voting is a crucial link in the chain of stewardship responsibilities we execute on behalf of our clients. Each vote represents both the privileges and the responsibilities that come with owning a company's equity instruments.

We take our responsibility to vote our clients' shares very seriously - taking into account both high-level principles of corporate governance and company-specific circumstances. Our overarching objective is to cast votes to foster long-term, sustainable success for the company and its investors.

T. Rowe Price portfolio managers are ultimately responsible for the voting decisions within the strategies they manage. They receive recommendations and support from a range of internal and external resources:

- The T. Rowe Price ESG Committee
- Our global industry analysts
- Our specialists in corporate governance and responsible investment
- ISS, our external proxy advisory firm

Our proxy voting program serves as one element of our overall relationship with corporate issuers. We use our voting power in a way that complements the other aspects of our relationship with these companies, including engagement, investment diligence, and investment decision-making.

SUMMARY OF MAJOR PROPOSAL ITEMS

The following table breaks down voting records into categories. Some categories, such as the election of directors, are universal across the markets where we invest. Other voting issues are unique to select regions. For management-sponsored proposals, a vote "FOR" is a vote aligned with the board's recommendation. For shareholder-sponsored proposals, a vote "FOR" is **generally** a vote contrary to the board's recommendation.

Proposals Sponsored by Company Management (Number of Proposals)		
	% Voted w/Mgmt	% Voted Against Mgmt
Add/Amend anti-takeover provisions (0)	0%	0%
Reduce/repeal anti-takeover provisions (1)	100%	0%
Appoint or ratify auditors (52)	100%	0%
Capital structure provisions (53)	100%	0%
Compensation - All types (90)	94%	6%
Director and auditor compensation (13)	100%	0%
Employee stock purchase plans (8)	100%	0%
Other equity compensation plans (15)	80%	20%
Executive compensation: Say on Pay (54)	96%	4%
Election of Directors, uncontested (426)	89%	11%
Election of Directors, contested (0)	0%	0%
Amend/adopt shareholder rights (3)	100%	0%
Mergers, acquisitions and reorganizations (7)	100%	0%
Routine/procedural proposals (57)	93%	7%
Proposals Sponsored by Shareholders (Number of Proposals)		
	% Voted w/Mgmt	% Voted Against Mgmt
Remove anti-takeover provisions (2)	100%	0%
Compensation-related proposals (1)	100%	0%
Separate Chair and CEO roles (1)	0%	100%
Amend/adopt shareholder rights (3)	33%	67%
Social/environmental proposals - All types (14)	43%	57%
Social proposals (9)	33%	67%
Disclose political/lobbying activity (2)	0%	100%
Environmental proposals (3)	100%	0%
All Proposals (Number of Proposals)		
	% Voted w/Mgmt	% Voted Against Mgmt
Total Management Proposals (689)	92%	8%
Total Shareholder Proposals (21)	48%	52%
Total Proposals (710)	90%	10%

SIGNIFICANT VOTES

The definition of a significant vote can vary across the investment industry. At T. Rowe Price, meetings may be tagged as significant where the situation is particularly contentious, or the vote illustrates a key aspect of our voting approach. Detailed below is the summary of a resolution, how we voted, and our rationale for that voting decision. T. Rowe Price portfolio managers decide how to vote on the proxy proposals of companies in their portfolios and, as a result, may not all vote the same.

This case study describes proxy voting being carried out on behalf of the fund. This material is for informational purposes only and is not intended as an offer or recommendation concerning investments, investment strategies, products, and account types.

CASE STUDY: AstraZeneca – Agenda item number 7	
Summary of the resolution(s)	Agenda item number 7: Approve Remuneration Policy
Country	UK
Company description	AstraZeneca is a global biopharmaceutical company.
Date of vote	April 11, 2024
Meeting type	Annual
Proponent	Management
How we voted	Agenda item number 7: Against
Rationale for the voting decision(s)	<p>This item was flagged as potentially contentious because the chief executive officer's (CEO) long-term incentive plan (LTIP) grant would rise from 650% to 850%, which is very high in the European context. In addition, this was taking place when the CEO's bonus was increased by an extra +50% of base salary.</p> <p>The uplift of the LTIP grant to 850% is outsized for a European company. Given the importance we place on social equity, Impact voted AGAINST the item. This reinforced the stance Impact took at the 2021 AGM when the remuneration policy was previously updated to again include a significant LTIP uplift.</p>

IMPORTANT INFORMATION

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298 AFSL 240975) is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Stock Exchange (ASX:EQT). Equity Trustees and T. Rowe Price Australia Limited ("TRPAU") (ABN: 13 620 668 895 and AFSL: 503741) are, respectively, the responsible entity and investment manager of the T. Rowe Price Australian Unit Trusts.

A Target Market Determination for each T. Rowe Price Australian Unit Trust (or class of units in a Trust) is available here (www.eqt.com.au/insto). It describes who the financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where Equity Trustees Limited, the responsible entity of the T. Rowe Price Australian Unit Trusts may need to review the Target Market Determination for the financial product.

Past performance is not a reliable indicator of future performance. The price of any fund may go up or down. Investment involves risk including a possible loss to the principal amount invested. For general information purposes only, does not take into account the investment objectives, financial situation or needs of any particular investor. For further details, please refer to each fund's product disclosure statement and reference guide which are available from Equity Trustees (www.eqt.com.au/insto) and TRPAU (www.troweprice.com.au/investor).

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date noted on the material and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

This document has been prepared without taking account of any person's individual objectives, financial situation or needs. A person should, before making any investment decisions, consider the appropriateness of the information in this document and seek independent professional advice having regard to their objectives, financial situation and needs.

Any person should consider the relevant product disclosure statement ("PDS") in relation to the fund(s) named in this document (if any) before making a decision in relation to the relevant product. Contact Equity Trustees Limited, the responsible entity and T. Rowe Price Australia Limited, the investment manager, for a copy of the PDS.

© 2024 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/ or apart, trademarks of T. Rowe Price Group, Inc.

202407-3752598

202408-3823545